

**Amendments to the Claims:**

Claims 1-152 (Cancelled)

153. (New) Use of a p38 inhibitor for manufacturing a medicament for treating or preventing a condition characterized by the activation of the innate immune system wherein the condition is a skin or hair condition, and is selected from among: hair loss, vitiligo, and dermal scars.

154. (New) A use of claim 153 where the p38 inhibitor is selected from among: pyridinylimidazoles, substituted pyrazoles, substituted pyridyls, quinazoline derivatives, aryl ureas, heteroaryl analogues, substituted imidazole compounds, and substituted triazole compounds.

155. (New) Use of a p38 inhibitor for manufacturing a medicament for treating a skin condition selected from among vitiligo and dermal scarring, where the p38 inhibitor is administered topically.

156. (New) A use of claim 155 wherein the dermal scarring is incident to acne.

157. (New) Use of a composition containing a neurotoxin and a neuron growth inhibitor for manufacturing a medicament for treating a condition by inhibition of neurotransmission of a neurotransmitter.

158. (New) A use of claim 157 wherein the neuron growth inhibitor inhibits neuron collateral sprouting.

159. (New) A use of claims 157 or 158 where the condition is selected from among localized dystonia, a thyroid condition, a neurological disorder, a muscle injury, a urological condition, an optical condition, a dermatological condition, a condition characterized by snoring, and a wound.

160. (New) A use of claims 157, 158 or 159 where

a. the neurotoxin is selected from among botulinum toxin, tetanus toxin, curare, bungarotoxin, saxitoxin, and tetrodotoxin; and,

b. the neuron growth inhibitor is selected from among a Trk receptor inhibitor, a Ras inhibitor, a Raf kinase inhibitor, a Rap-1 inhibitor, an MEK inhibitor, an NF- $\kappa$ B inhibitor, an ERK inhibitor, a PKA inhibitor, a PKC inhibitor, a p53 inhibitor, and a growth factor inhibitor; and,

Preliminary Amendment Dated September 5, 2006

c. an inhibitor of an isozyme, derivative, splicing variant, activator or effector of any of the compositions set forth in subsection (b).